U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 23 results

Status:
US Approved Rx (2023)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarc...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...
Status:
US Approved Rx (2014)
First approved in 1997

Class (Stereo):
CHEMICAL (ABSOLUTE)



Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopido...
Status:
US Approved Rx (1999)
First approved in 1991

Class (Stereo):
CHEMICAL (ACHIRAL)



Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Ticlopidine is a prodrug that is metabolized to an as yet undetermined metabolite that acts as a platelet...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Elinogrel, previously known as PRT060128 or PRT128, is a direct-acting, reversible P2Y12 inhibitor for both intravenous and oral administration. Elinogrel has been tested in 2 phase II studies for the treatment of acute coronary syndrome, myocardial ...
Status:
US Approved Rx (2023)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarc...
Status:
US Approved Rx (2023)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarc...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformatio...